This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

iRhythm Holdings, Inc.
11/5/2026
Hello, everyone. Thank you for joining us, and welcome to the iRhythm Holdings, Inc. Q3 2026 Earnings Conference Call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Francis Pruel, Head of Strategic Finance and Investor Relations. Francis, please go ahead.
Thank you, Operator, and thank you all for joining iRhythm's third quarter 2026 earnings call. With me today are Quentin Blackford, iRhythm's President and Chief Executive Officer, and Dan Wilson, our Chief Financial Officer. Before we begin… Please note that management will make forward-looking statements within the meaning of federal securities laws under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our intentions, beliefs, and expectations about future events, strategy, competition, products, operating plans, and performance. Forward-looking statements on this call are based on current estimates and assumptions, involve risks and uncertainties, and actual results may differ materially. These statements are made as of today, November 5, 2026, and are time sensitive. For a discussion of risks and uncertainties, please refer to our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the SEC. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP. Unless otherwise noted, all references to financial measures on this call are presented on a non-GAAP basis. These non-GAAP measures should not be considered in isolation or as a substitute for or superior to GAAP results. Reconciliations to the most directly comparable GAAP measures can be found in our earnings release and the slides accompanying today's call. And with that, I'll turn the call over to Quentin.
Good afternoon, everyone, and thank you for joining us for our third quarter earnings call. We are pleased with iRhythm's progress in the quarter, and our results reflect the positive growth trajectory of our business across multiple channels, as well as the meaningful operating leverage we continue to generate as we scale the Zio platform. I'll begin with the key highlights from the quarter and provide updates on our strategic priorities before turning the call over to Dan for a more detailed review of our financial results and outlook. Third quarter revenue was $221.6 million, up nearly 15% year-over-year against our toughest comparison of the year, as we lapped more than 30% growth in the third quarter of 2025. Overall performance was consistent with our guidance, with our Core Zeo Monitor business again outperforming our expectations. That Monitor business continues to be driven by durable demand and sustained momentum across primary care, innovative channels, and international markets. We continue to expand the cardiac diagnostics market both within traditional cardiology settings and across these underpenetrated opportunities. The strong performance in the Core Monitor business was offset by Zeo AT, where revenue was roughly flat compared to the prior year. Thank you for joining us. Now I'm going to spend some time talking about the strategy we continue to execute to evolve from a leader in ambulatory cardiac monitoring into a broader cardiac and vitals monitoring and intelligence platform. First I will walk through the opportunities that Vital Connect brings and then provide an update on the ZOMCT program. As a reminder, we closed the Vital Connect acquisition on October 5th, well ahead of our prior expectation of closing by year-end. This acquisition is an exciting milestone for iRhythm, as it significantly expands our capabilities and market opportunity. It also immediately adds a complimentary FDA-cleared mobile cardiac telemetry offering to our portfolio. VitalConnect's platform can be used to monitor multiple physiological parameters, including ECG, heart rate, respiratory rate, and body temperature, as well as fall detection and the ability to connect additional parameters such as blood pressure and pulse oximetry. Its platform supports ambulatory, inpatient, remote patient monitoring, and hospital-to-home care, expanding our relevance across the patient journey and creating new opportunities within hospitals and health systems. VitalConnect will serve as our immediate MCT growth platform while also providing important multi-modality capabilities. It supports MCT, cardiac event monitoring, extended monitoring, and Holter use cases with up to 30 days of monitoring service, live look and functionality, and the flexibility to transition between monitoring pathways when clinically appropriate. Thank you for joining us. Thank you for listening. Realizing the full potential of Vital Connect requires more than expanding our product portfolio. We are integrating the technology into our customer EHR systems, incorporating Vital Connect's Vista Center data and Live Look-In functionality, and enabling multi-modality workflows. These capabilities are essential to driving broader adoption, particularly among our existing large integrated health system customers. In parallel, we are preparing the business to scale across supply chain, clinical operations, customer support, technology, quality, and implementation capacity. The earlier-than-expected transaction close allows us to accelerate commercial training into the first two weeks of November, enabling our teams to begin engaging customers while we continue building the integration and operating infrastructure required for broader adoption. Our focus is squarely on executing a disciplined integration, and our initial progress reinforces our confidence in the significant value and new growth opportunities this acquisition will unlock for iRhythm. Thank you for joining us. Mervin Smith, Mervin Smith, Mervin Smith, The addition of VitalConnect's capabilities open up what we believe will be a significant, immediate growth opportunity, and this decision will allow us to focus on unlocking that value for patients and shareholders, while being deliberate in our planning and preparation to, in turn, maximize the value of our planned next-generation ZOMCT, our integrated MCT portfolio, in your investment. That said, we've made tangible progress with ZOMCT that gives us greater visibility into the path ahead. We've begun producing and testing the actual ZOMCT system in the configuration we intend to submit to the FDA, and we are advancing the remaining verification, documentation, and regulatory work. We expect to submit our ZOMCT filing to the FDA in 2027. ZOMCT is an important part of our long-term portfolio as it is designed to build upon the simplicity of patients' and physicians' value in ZOAT by providing an extended wear period and enhanced detection algorithms. We believe that an MCT portfolio today of ZOAT and Vital Connect give us an immediate, best-in-class mobile cardiac telemetry portfolio that will further improve with the future introduction of ZOMCT, which we expect will eventually replace ZOAT. Turning next to ZOAT, we remain confident in its clinical value in the complementary set of solutions it creates with Vital Connect. Thank you for joining us. ZOAT performance was below our expectations during the quarter, where revenue was flat compared to the prior year versus our expectations of growth generally in line with our overall business. Based on customer and commercial feedback, we believe this was in part driven by delayed purchasing decisions following the announcement of a Vital Connect acquisition as they considered the combined portfolio and the potential availability of Vital Connect through the iRhythm sales channel. Thank you for watching. Thank you for joining us. We believe our Vital Connect and ZUAT portfolio provides a strong foundation to participate more broadly in the MCT market in the near term, with ZUMCT remaining an important addition to the portfolio over time. Turning to innovative channels in primary care, we continue to see encouraging momentum as we expand cardiac monitoring beyond traditional cardiology settings. What is becoming clearer is that the market opportunity ahead of us is not simply about taking market share. It is about expanding our serviceable market in a meaningful way. There is a measurable care gap for patients at risk of arrhythmias that can be addressed through better patient identification, better clinical workflow, and better access. Thank you for joining us. Thank you. Thank you. Thank you. Starting with Innovative Channels, which was our fastest growing business during the quarter once again, our partners increasingly view Zio as a way to identify and engage appropriate patients earlier rather than waiting for these patients to reach a specialist after repeated symptoms or acute care events. Importantly, our partners can make these determinations with confidence as our early pilots have demonstrated greater than 85% accuracy in identifying patients with clinically relevant arrhythmias before they enter the diagnostic process. Primary care, more broadly, is also an important part of our upstream strategy. Zio's rule-in and rule-out capability can help primary care clinicians begin their diagnostic process earlier, enabling cardiologists to focus on patients who need higher acuity care. We recently launched targeted initiatives through the Patient Point Network, coordinating arrhythmia education for patients, physicians, and office staff. Thank you for joining us. Thank you for joining us. The next phase is to turn these programs into a repeatable playbook through provider education, patient activation, targeted primary care coverage, workflow and EHR enablement, and continued clinical and economic evidence generation. Thank you for watching. Thank you for joining us. We also submitted an application to the FDA for a pediatric indication for our Zio Monitor, representing another potential meaningful opportunity to meet care needs for these patients and expand our core monitoring market. If cleared by the FDA, this would represent iRhythm's first pediatric indication, and we are excited about the potential to serve this market segment. We are also excited about recent clinical developments. In October, we published results from our Excalibur study in clinical cardiology, extending the evidence generated through Camelot and Avalon into the Medicare Advantage population. The results once again demonstrated strong diagnostic performance with Zio long-term cardiac monitoring, along with lower downstream healthcare utilization and cost across a large, diverse insured population. Excalibur, Camelot, and Avalon And with respect to the FDA warning letter, as previously noted, we have completed our remediation activities, updated the agency accordingly, and are expecting a follow-up inspection, although we don't yet know when that will occur. As we look ahead, I believe iRhythm is well positioned to execute our long-term strategy. Our core business continues to generate durable growth and meaningful operating leverage. We are expanding our reach across primary care and innovative channels, investing in new clinical applications, and strengthening our operating foundation. With Vital Connect, we have meaningfully expanded our addressable market, strengthened our immediate MCT offering, and created a platform to serve patients' providers across a broader continuum of care. Our priorities remain focusing on disciplined execution and delivering sustained volume-led growth and continued profitability and free cash flow generation. With that, I'll turn the call over to Dan.
You're reading a preview of the IRTC Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing